Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear receptor subfamily 4 group A member 3 (NR4A3), also known as Neuron-derived orphan receptor 1 (NOR1), is a member of the NR4A orphan nuclear receptor family that functions as an activity-dependent transcription factor (UniProt P41153). It is rapidly induced by a variety of physiological stimuli, including growth factors and cytokines, and plays a pivotal role in regulating cell cycle progression, apoptosis, and systemic metabolism (PubMed: 24011540). In oncology, NR4A3 is a critical driver of extraskeletal myxoid chondrosarcoma (EMC), where it is frequently found as a fusion protein resulting from chromosomal translocations, most commonly EWSR1-NR4A3 (PubMed: 15188353). Conversely, in the context of hematology, NR4A3 acts as a potent tumor suppressor; its loss or downregulation is a key event in the pathogenesis of acute myeloid leukemia (AML) (PubMed: 28235200). Beyond cancer, NR4A3 is involved in vascular biology, where it regulates the proliferation of vascular smooth muscle cells and the inflammatory response in atherosclerotic lesions (PubMed: 17065454). Although it is classified as an orphan receptor because it lacks a known endogenous ligand, its activity can be modulated by small molecules like 6-mercaptopurine and synthetic agonists, making it an attractive target for therapeutic intervention in metabolic and malignant disorders.
Modulation of transcriptional activity by binding as a monomer to NGFI-B response elements (NBRE) or as a homodimer/heterodimer to Nur-responsive elements (NurRE) to regulate downstream gene expression.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear receptor subfamily 4 group A member 3 (NR4A3) (NR4A3).